TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Change in Account Payables of $1.0 million for Q1 2026, up 87.28% year-over-year from $558000.0 in Q1 2025, and up 120.62% quarter-over-quarter from -$5.1 million in Q4 2025.
TScan Therapeutics (TCRX) Change in Account Payables (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Change in Account Payables for 7 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 87.28% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$2.5 million (down 185.21% YoY), while the FY2025 annual figure was -$3.0 million, down 251.0% from the prior year.
- Change in Account Payables advanced to $1.0 million in Q1 2026 per TCRX's latest filing, from -$5.1 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.9 million in Q3 2025 and bottomed at -$5.1 million in Q4 2025.
- Historically, Change in Account Payables has averaged $29647.1 across 5 years, with a median of $408000.0 in 2022.
- Annual changes were most pronounced in 2024 — Change in Account Payables jumped 475.46% — and 2025, when it plunged 615.46%.
- TScan Therapeutics' Change in Account Payables stood at $414000.0 in 2022, then slumped by 254.83% to -$641000.0 in 2023, then soared by 253.35% to $983000.0 in 2024, then slumped by 615.46% to -$5.1 million in 2025, then soared by 120.62% to $1.0 million in 2026.
- Business Quant data shows TCRX's Change in Account Payables at $1.0 million in Q1 2026, -$5.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 843,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 843,000.00 |
| Jun 30, 2026 | 843,000.00 |
| Mar 31, 2026 | 1.05 Mn |
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | -5.07 Mn |
| Dec 31, 2025 | -5.07 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -435,000.00 |
| Jun 30, 2025 | -435,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Dec 31, 2024 | 983,000.00 |
| Dec 31, 2024 | 983,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 396,000.00 |
| Mar 31, 2024 | -410,000.00 |
| Mar 31, 2024 | -410,000.00 |